Fig. 2From: The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trialTumor response assessment according to the RECIST v1.1. A Best percentage change from baseline in target lesion. B Duration of responsesBack to article page